Home: Web Guide 1: Editor

Welcome to Colorectal Cancer Update

In recent years, treatment options for both primary and metastatic colorectal cancer have improved with the availability of a number of new, effective chemotherapeutic agents and combinations. The future looks even brighter, as many more novel therapies and regimens fill the pipeline.

This new series will provide practicing oncologists access to the latest developments in clinical research. Utilizing an educational model developed over the last 14 years in breast cancer, Colorectal Cancer Update focuses on in-depth interviews with investigators specializing in colorectal cancer clinical research. The perspectives, opinions and experiences of these research leaders allow busy, practicing oncologists to take away practical strategies that can be utilized in daily patient care.

As in our breast cancer series, this audio program is supplemented by a website — ColorectalCancerUpdate.com — which contains full transcripts from the interviews and related links to journal articles, abstracts and protocols. Colorectal cancer is a disease with many more therapeutic options than even five years ago. Our goal is to provide valuable research information and viewpoints that can be applied to clinical decision-making for the thousands of men and women with this disease. We look forward to many more issues.

—Neil Love, MD
Editor

Select Agents in Phase II/III Colorectal Clinical Trials in the NCI’s PDQ data base
Avastin®
(bevacizumab)
BiCNU®
(carmustine)
BMS-247550 (investigational epothilone B analog)
Camptosar® (irinotecan, CPT-11)
Eloxatine® (oxaliplatin)
Erbitux® (cetuximab, IMC-C225)
Ergamisol® (levamisole)
Herceptin® (trastuzumab)
Iressa® (ZD 1839)
Panorex® (edrecolomab)
Rubivive® (rubitecan, RFS 2000)
Taxol® (paclitaxel)
Thalomid® (thalidomide)
Xeloda® (capecitabine)

 

 

Home

Editor's Office

 

 

Terms of use and general disclaimer
© NL Communications, Inc. 2002. All rights reserved.